AKBA

Company Overview — What Does Akebia Therapeutics, Inc. Do?

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics, Inc. (AKBA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John P. Butler and employs approximately 430 people, headquartered in Cambridge, Massachusetts. With a market capitalization of $378M, AKBA is one of the notable companies in the Healthcare sector.

Akebia Therapeutics, Inc. (AKBA) Stock Rating — Hold (April 2026)

As of April 2026, Akebia Therapeutics, Inc. receives a Hold rating with a composite score of 34.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.AKBA ranks #1,920 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Akebia Therapeutics, Inc. ranks #202 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AKBA Stock Price and 52-Week Range

Akebia Therapeutics, Inc. (AKBA) currently trades at $1.40. The stock lost $0.01 (0.7%) in the most recent trading session. The 52-week high for AKBA is $4.08, which means the stock is currently trading -65.7% from its annual peak. The 52-week low is $1.14, putting the stock 22.8% above its annual trough. Recent trading volume was 2.1M shares, reflecting moderate market activity.

Is AKBA Overvalued or Undervalued? — Valuation Analysis

Akebia Therapeutics, Inc. (AKBA) carries a value factor score of 56/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The price-to-book ratio stands at 11.34x, versus the sector average of 2.75x. The price-to-sales ratio is 1.71x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, AKBA trades at 21.38x EV/EBITDA, versus 6.34x for the sector.

Overall, AKBA's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Akebia Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Akebia Therapeutics, Inc. (AKBA) earns a quality factor score of 32/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -40.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -3.5% versus the sector average of -33.1%.

On a margin basis, Akebia Therapeutics, Inc. reports gross margins of 79.3%, compared to 71.5% for the sector. The operating margin is 5.1% (sector: -66.1%). Net profit margin stands at -10.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 34.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AKBA Debt, Balance Sheet, and Financial Health

Akebia Therapeutics, Inc. has a debt-to-equity ratio of 148.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.55x, suggesting adequate working capital coverage. Total debt on the balance sheet is $48M. Cash and equivalents stand at $166M.

AKBA has a beta of 1.01, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Akebia Therapeutics, Inc. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Akebia Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Akebia Therapeutics, Inc. reported revenue of $216M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-13M. Gross margin was 79.3%. Operating income came in at $20M.

In FY 2025, Akebia Therapeutics, Inc. reported revenue of $236M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-5M. Gross margin was 83.3%. Revenue grew 47.5% year-over-year compared to FY 2024. Operating income came in at $23M.

In Q3 2025, Akebia Therapeutics, Inc. reported revenue of $59M and earnings per share (EPS) of $0.00. Net income for the quarter was $540,000. Gross margin was 84.0%. Revenue grew 57.0% year-over-year compared to Q3 2024. Operating income came in at $4M.

In Q2 2025, Akebia Therapeutics, Inc. reported revenue of $62M and earnings per share (EPS) of $0.00. Net income for the quarter was $247,000. Gross margin was 84.1%. Revenue grew 43.1% year-over-year compared to Q2 2024. Operating income came in at $14M.

Over the past 8 quarters, Akebia Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $44M to $216M. Investors analyzing AKBA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AKBA Dividend Yield and Income Analysis

Akebia Therapeutics, Inc. (AKBA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AKBA Momentum and Technical Analysis Profile

Akebia Therapeutics, Inc. (AKBA) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

AKBA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Akebia Therapeutics, Inc. (AKBA) ranks #202 out of 838 stocks based on the Blank Capital composite score. This places AKBA in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AKBA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AKBA vs S&P 500 (SPY) comparison to assess how Akebia Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

AKBA Next Earnings Date

No upcoming earnings date has been announced for Akebia Therapeutics, Inc. (AKBA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AKBA? — Investment Thesis Summary

Akebia Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 32/100 flags below-average profitability. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 36/100) increases portfolio risk.

In summary, Akebia Therapeutics, Inc. (AKBA) earns a Hold rating with a composite score of 34.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AKBA stock.

Related Resources for AKBA Investors

Explore more research and tools: AKBA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AKBA head-to-head with peers: AKBA vs AZN, AKBA vs SLGL, AKBA vs VMD.